L

Lumos Diagnostics Holdings Ltd
ASX:LDX

Watchlist Manager
Lumos Diagnostics Holdings Ltd
ASX:LDX
Watchlist
Price: 0.038 AUD 2.7% Market Closed
Market Cap: 28.4m AUD
Have any thoughts about
Lumos Diagnostics Holdings Ltd?
Write Note

Net Margin
Lumos Diagnostics Holdings Ltd

-77.2%
Current
-178%
Average
2.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-77.2%
=
Net Income
-8.6m
/
Revenue
11.1m

Net Margin Across Competitors

Country AU
Market Cap 27.7m AUD
Net Margin
-77%
Country JP
Market Cap 7T JPY
Net Margin
24%
Country CH
Market Cap 37.8B CHF
Net Margin
12%
Country DK
Market Cap 178.7B DKK
Net Margin
19%
Country US
Market Cap 16.1B USD
Net Margin
11%
Country KR
Market Cap 10.5T KRW
Net Margin
-358%
Country CN
Market Cap 49B CNY
Net Margin
42%
Country US
Market Cap 6.5B USD
Net Margin
29%
Country CA
Market Cap 6.4B USD
Net Margin
-8%
Country UK
Market Cap 4.7B GBP
Net Margin
7%
Country US
Market Cap 5.7B USD
Net Margin
9%
No Stocks Found

Lumos Diagnostics Holdings Ltd
Glance View

Market Cap
28.4m AUD
Industry
Health Care

Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

LDX Intrinsic Value
0.169 AUD
Undervaluation 78%
Intrinsic Value
Price
L
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-77.2%
=
Net Income
-8.6m
/
Revenue
11.1m
What is the Net Margin of Lumos Diagnostics Holdings Ltd?

Based on Lumos Diagnostics Holdings Ltd's most recent financial statements, the company has Net Margin of -77.2%.